地尔硫卓杂质8 | 86408-42-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫氮卓类
• 中文名称: 地尔硫卓杂质8
• 英文名称: N,O-didesmethyl,O-desacetyldiltiazem
• 英文别名: N,O-Didemethyl-deacetyldiltiazem；(2S,3S)-2,3-Dihydro-3-hydroxy-2-(4-hydroxyphenyl)-5-[2-(methylamino)ethyl]-1,5-benzothiazepin-4(5H)-one；Deacetyl-N,O-didemethyldiltiazem；(2S,3S)-3-hydroxy-2-(4-hydroxyphenyl)-5-[2-(methylamino)ethyl]-2,3-dihydro-1,5-benzothiazepin-4-one
• CAS: 86408-42-6
• 化学式: C₁₈H₂₀N₂O₃S
• 分子量: 344.434
• InChiKey: ZTRZZXJIQHVVGS-SJORKVTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  98.1
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Methods For Treating A Condition Characterized By Dysfunction In Protein Homeostasis
  申请人：Segatori Laura

  公开号：US20090203605A1

  公开（公告）日：2009-08-13

  Methods are provided for treating conditions characterized by dysfunction in protein homeostasis in a patient in need thereof. A method for treating a condition characterized by dysfunction in protein homeostasis in a patient in need thereof is provided which comprises administering to the patient a proteostasis regulator in an amount effective to improve or restore protein homeostasis, and to reduce or eliminate the condition in the patient or to prevent its occurrence or recurrence. The condition can be a loss of function disorder such as a lysosomal storage disease, or a gain of function disorder such as an aging associated disease.

  提供了一种用于治疗患有蛋白质稳态功能障碍的患者的方法。提供了一种治疗患有蛋白质稳态功能障碍的患者的方法，包括向患者施用一种蛋白稳态调节剂，其有效量能够改善或恢复蛋白质稳态，并减少或消除患者的疾病，或预防其发生或复发。该疾病可以是功能丧失性疾病，如溶酶体贮积病，或功能增强性疾病，如与衰老相关的疾病。
• [EN] METHODS FOR TREATING A CONDITION CHARACTERIZED BY DYSFUNCTION IN PROTEIN HOMEOSTASIS<br/>[FR] MÉTHODES DE TRAITEMENT D'UN ÉTAT PATHOLOGIQUE CARACTÉRISÉ PAR UN DYSFONCTIONNEMENT DE L'HOMÉOSTASIE DES PROTÉINES
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2009100037A1

  公开（公告）日：2009-08-13

  Methods are provided for treating conditions characterized by dysfunction in protein homeostasis in a patient in need thereof. A method for treating a condition characterized by dysfunction in protein homeostasis in a patient in need thereof is provided which comprises administering to the patient a proteostasis regulator in an amount effective to improve or restore protein homeostasis, and to reduce or eliminate the condition in the patient or to prevent its occurrence or recurrence. The condition can be a loss of function disorder such as a lysosomal storage disease, or a gain of function disorder such as an aging associated disease.